Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 46Lymphoma, Non-Hodgkin 33Lymphoma, Large B-Cell, Diffuse 32Lymphoma, Mantle-Cell 25Lymphoma, Follicular 21Hodgkin Disease 21Lymphoma, Large-Cell, Immunoblastic 16Glioblastoma 16Leukemia, Lymphocytic, Chronic, B-Cell 15Burkitt Lymphoma 15Brain Neoplasms 14Multiple Myeloma 13Gliosarcoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Central Nervous System Neoplasms 12Leukemia 10Neoplasms, Plasma Cell 9Lymphoma, B-Cell, Marginal Zone 9Glioma 9Astrocytoma 9Oligodendroglioma 5Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, T-Cell 4Lymphoma, B-Cell 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3

Interventions

Doxorubicin 5Cyclophosphamide 5Vincristine 4Prednisone 4Brentuximab Vedotin 4Etoposide 3etoposide phosphate 2Prednisolone 2Bortezomib 2tazemetostat 1prednylidene 1pembrolizumab 1duvelisib 1deltacortene 1Vorinostat 1Panobinostat 1Nivolumab 1Methylprednisolone 1Melphalan 1Gemcitabine 1Cytarabine 1Cisplatin 1Carmustine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Enteropathy-Associated T-Cell Lymphoma × Carmustine × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡